A recent report by Forbes.com highlights the tremendous growth expected in the cannabidiol (CBD) market over the next three years. The report also explains that hemp-derived CBD will account for $450 million of the estimated total sales of $2.1B by 2020.
As quoted in the report:

The cannabidiol (CBD) market is estimated to grow by 700% by 2020, according to Forbes. A new report by market intelligence firm Hemp Business Journal projects that the CBD market will grow to $2.1 billion by 2020, an astronomical jump in value compared to last year’s CBD market of $202 million.
CBD is one of the more than 85 cannabinoids so far identified in marijuana and hemp. Unlike the better-known compound tetrahydrocannabinol (THC), CBD is not psychoactive, meaning it won’t cause a high. Thousands of studies have shown that CBD possesses an array of therapeutic benefits, including antioxidant and neuroprotective properties.
“In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only — this is in addition to the 28 states plus DC that have legalized medical marijuana,” Matt Karnes of Greenwave Advisors told Forbes, believing the growing CBD market will exceed the estimations by Hemp Business Journal.
The Hemp Business Journal report estimates that $450 million of the projected $2.1 billion in sales by 2020 will come from hemp-based sources. The hemp-derived CBD market was $90 million in 2015.
CBD that is derived from hemp is legal to import and purchase in all 50 U.S. states, without a prescription. Cannabidiol itself isn’t listed in the Controlled Substances Act like THC and marijuana.
Current market leader Medical Marijuana, Inc. told Forbes that it pulls in over $800,000 in retail hemp-based CBD sales per month. The company’s sales are expected to be $9 million in 2016, up from $3.4 million in 2013.
Being the only CBD company on the market at the time, Medical Marijuana, Inc. reached $14.5 million in sales in 2014, and while their customer count has increased since then, an increase in competition and a drop in prices has affected sales figures. Its investment company, Axim Biotechnologies, holds a patent and license for a CBD chewing gum called CanChew.
Venture capital firm General Hemp, which has controlling interest in Medical Marijuana, Inc., made $34 million in CBD sales between 2014 and 2016, not including Medical Marijuana, Inc. companies.
With the recent influx in competition and a lack of regulation, consumers must educate themselves to ensure they buy high-quality CBD. Medical Marijuana, Inc. says that the CBD oil used in its Real Scientific Hemp Oil and Dixie Botanicals products is derived from hemp grown in Austria and that it’s tested several times for purity and cannabinoid content.
According to Forbes, data from Headset Research says that it’s difficult for consumers to know what they’re getting when they purchase CBD products. The information offered on most product labels is limited.
“Many order large vats of CBD oil that is produced from Chinese industrial hemp and cut that into their products. This makes it difficult for those who grow and extract CBD locally to compete and consumers aren’t currently educated enough to have a preference for ‘homegrown’ CBD products.”
The best play for consumers is “to do their homework,” Forbes suggests, by looking into where a company acquires its CBD. Finding out which products are best will likely include trial and error, the publication says.


 

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less